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Dear Sir,
The widespread availability of recombi-
nant human erythropoietin (rHU-EPO) is
one of the greatest advances in clinical neph-
rology. Approximately 90–95% of dialysis
patients treated with rHu-EPO respond with
an improvement in their anemia, but indi-
vidual doses may vary considerably. The
most important factors causing this varia-
tion are acute or chronic inflammatory pro-
cesses which may lead to marked resistance
to rHu-EPO. It is a well-known fact that
exposure of patient’s blood to even mildly
contaminated dialysate contributes to the
systemic inflammatory syndrome of uremia
by induction of cytokine synthesis [1]. How-
ever, there are no data indicating whether
differences in the microbiological quality of
the dialysate may affect the response to rHu-
EPO in patients receiving regular hemodial-
ysis.
The aim of our prospective cross-over
investigation was to compare the effect of
potentially contaminated, commercial (un-
filtered) and online produced, ultrapure dial-
ysate on rHu-EPO doses. Twenty-four stable
anuric dialysis patients gave informed con-
sent to participate in the study which was
approved by the local ethics committee.
They all had normocytic normo-chromic
anemia of end-stage renal disease and nor-
mal levels of folic acid, vitamin B12 and
ferritin. None of the patients had acute or
chronic infection, inflammatory disease,
malignancy or chronic bleeding disorders or
used immunosuppressive drugs or angioten-
sin-converting enzyme inhibitors. Hemodi-
alysis was performed with volumetrically
controlled ultrafiltration (MTS 4008, Frese-
nius, Bad Homburg, Germany) and biocom-
patible high-flux dialyzers (Polysulfone, F60
Fresenius, Bad Homburg, Germany). The
bicarbonate dialysate was either commercial
or ultrafiltrated using polysulfone filters.
Each treatment session lasted 3–5 h, with
blood flow rates between 250 and 350 ml/
min, and dialysate flow rates at 500 ml/min.
Twelve patients each were randomly as-
signed to treatment with unfiltered (com-
mercial) dialysate for 3 months and crossed
over to ultrafiltrated dialysate for another 3
months or were treated in the reverse order.
The microbiological quality of the dialysate
was checked monthly. Plasma C-reactive
protein (CRP) levels and circulating inter-
leukin-6 concentrations were measured by
highly sensitive enzyme-linked immunosor-
bent assays.
There were no statistically significant dif-
ferences in the demographic characteristics
or treatment-associated parameters between
the 2 study groups at recruitment. Both
groups had comparable target hemoglobin
concentrations and rHu-EPO doses (ß-epoie-
tin, Boehringer, Mannheim, Germany) at
the start of the study (table 1).
In group I continuation of commercial
unfiltered dialysate (median 140, range 60–
400 CFU) did not result in a significant
change of hemoglobin levels (10.2 B 0.2 g/
dl), rHu-Epo doses (90 B 50 U/kg/week) or
inflammation as determined by CRP (1.1 B
0.2 mg/ml) or plasma IL-6 (55 B 15 pg/ml).
The change of the dialysate after 3 months,
however, caused a significant reduction in
rHu-EPO doses (60 B 31 U/kg/week, p !
0.05) despite comparable hemoglobin levels
(10.3 B 0.3 g/dl) and furthermore led to a
significant fall in CRP (0.6 B 0.2 mg/dl, p !
0.05) and IL-6 (35 B 10 pg/ml, p ! 0.05).
In group II change of the unfiltered to
ultrapure dialysate caused a significant re-
duction in rHu-EPO doses (62 B 32 U/kg/
week, p ! 0.05) despite comparable hemo-
globin levels (10.1 B 0.2 g/dl) and a signifi-
cant fall in CRP and IL-6 concentrations was
observed (0.7 B 0.2 mg/dl and 38 B 14 pg/
dl, p ! 0.05. Reinstitution of commercial
dialysate (median 120, range 40–400 CFU)
resulted in increased rHu-EPO doses (87 B
45 U/kg/week) to stabilize hemoglobin con-
centrations at comparable levels (10.2 B
0.3 g/dl) and led to an intensified systemic
inflammatory response as marked by rises
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Table 1. Patient characteristics at recruitment (mean B SD)
Group I Group II
Number of patients 12 12
Age, years 58B14 61B13
Gender, male/female 6/6 6/6
Time on dialysis, months 45B14 48B18
Weight, kg 72B16 76B13
Parathyroid hormone, pg/ml 133B15 121B36
Serum aluminium, Ìg/l 20B15 25B20
KT/V urea 1.3B0.3 1.4B0.2
Hemoglobin, g/dl 10.2B0.5 10.1B0.4
rHu-EPO, U/kg/week 92.5B52.5 85.7B46.8
CRP, mg/dl 1.2B0.2 1.4B0.4
IL-6, pg/ml 58B23 52B18
Table 2. Effects of commercial vs. ultrapure dialysate on rHu-EPO
doses (mean B SD)
Commercial
dialysate
Ultrapure
dialysate
Number of patients 24 24
Hemoglobin, g/dl 10.2B0.3 10.2B0.3
rHu-EPO, U/kg/week 87B44 61B30*
* p ! 0.05 vs. corresponding value of commercial dialysate.
in CRP (1.3 B 0.2 mg/dl) and IL-6 (61 B
16 pg/dl; table 2).
These data demonstrate that even mildly
contaminated commercial bicarbonate dial-
ysate causes chronic inflammation by induc-
tion of cytokine synthesis. Use of ultrapure
(filtered, pyrogen-free and sterile) dialysate
reduced the rHu-EPO doses required to
maintain hemoglobin levels via a reduction
in systemic inflammatory processes (ta-
ble 2).
The mechanisms underlying the in-
creased need for rHu-Epo doses in patients
treated with commercial dialysates may in-
clude suppression of endogenous erythropoi-
etin secretion, iron delivery and prolifera-
tion of erythrocyte precursors [2]. Recombi-
nant erythropoietin administration provides
a number of undisputed benefits to patients
undergoing maintenance dialysis, but adds
significantly to the costs of hemodialysis
treatment. Thus, efforts should be directed
at minimizing the dose of rHu-EPO to
achieve optimal target hemoglobin concen-
trations. The use of ultrapure bicarbonate
dialysate is inexpensive and undoubtedly
has clinical implications for the treatment of
anemia of chronic renal failure.
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